PCSK9:a new therapeutic target for cardiovascular calcification?
10.20039/j.cnki.1007-3949.2024.09.009
- VernacularTitle:PCSK9:心血管钙化的新治疗靶点?
- Author:
Xi GONG
1
;
Qiong XIANG
;
Yanyu CHEN
;
Zhihan TANG
;
Juan PENG
Author Information
1. 南华大学心血管疾病研究所动脉硬化学湖南省重点实验室湖南省动脉硬化性疾病国际科技创新合作基地,湖南省衡阳市 421001
- Keywords:
proprotein convertase subtilisin/kexin type 9;
cardiovascular calcification;
inflammation
- From:
Chinese Journal of Arteriosclerosis
2024;32(9):798-804
- CountryChina
- Language:Chinese
-
Abstract:
Proprotein convertase subtilisin/kexin type 9(PCSK9)comprised of 692 amino acids is the ninth mem-ber of protease family.It binds to the low-density lipoprotein receptor(LDLR),leading to elevated levels of circulating low-density lipoprotein cholesterol(LDLC),which can lead to a number of cardiovascular diseases,and among then the re-lationship with cardiovascular calcification has recently received attention.Cardiovascular calcification is a kind of ectopic mineralisation in the cardiovascular system,which is mainly characterised by the production of mineral deposits in the vas-cular wall and vascular valves,and its pathogenesis is related to lipoprotein content,platelet activity,matrix vesicle(MV)release and inflammation,through which PCSK9 may be involved in the occurrence of cardiovascular calcification.Therefore,this article reviews the relationship between PCSK9 and cardiovascular calcification,emphasizing the specific role of PCSK9 in affecting cardiovascular calcification through various pathways,assisting in setting up emerging applica-tions of PCSK9 amid vessel biological science and recognize innovative molecular mechanisms for its treatment.
